ProCE Banner Activity

FAQs: Optimal Selection and Sequencing of Treatment for Patients With Aggressive B-Cell Lymphomas

Clinical Thought

In this commentary, expert faculty address frequently asked questions about the selection and sequencing of therapies for patients with aggressive B-cell lymphomas.

Released: January 31, 2023

Expiration: January 30, 2024



John Allan

John Allan, MD

Assistant Professor of Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

John P. Leonard

John P. Leonard, MD

Richard T. Silver Distinguished Professor of Hematology and Medical Oncology
Professor of Medicine
Weill Cornell Medicine
New York Presbyterian Hospital
New York, New York

Laurie H. Sehn

Laurie H. Sehn, MD, MPH

Chair, Lymphoma Tumour Group
BC Cancer
Vancouver, Canada

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from


Genmab US Inc and AbbVie

Karyopharm Therapeutics Inc

Regeneron Pharmaceuticals, Inc.


John N. Allan, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Epizyme, Genentech, Janssen, Pharmacyclics.

John P. Leonard, MD: consulting/advisor/speaker: AbbVie, Astellas, AstraZeneca, Bayer, BeiGene, Bristol-Myers Squibb, Calithera, Caribou Biosciences, Constellation, Eisai, Epizyme, Genmab, Grail, Incyte, Janssen, Karyopharm, Lilly, Merck, Mustang Bio, Pfizer, Roche/Genentech, Second Genome, Sutro.

Laurie H. Sehn, MD, MPH: consultant/advisor/speaker: AbbVie, AstraZeneca, BeiGene, Bristol-Myers Squibb/Celgene, Gilead/Kite, Incyte, Janssen, Merck, Roche/Genentech, Seattle Genetics, Teva, TG Therapeutics.